AA
MLTX icon

AlphaCentric Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

AlphaCentric Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,000
Closed -$706K – 261
2024
Q3 		$706K Buy
+14,000
New +$656K 0.52% 59

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AlphaCentric Advisors's MLTX Position: Q4 2024 in Review

AlphaCentric Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2024, closing a stake of 14,000 shares — an estimated $706K sold.

AlphaCentric Advisors first reported a position in MLTX in Q3 2024 and held it in 1 quarter. The position peaked at $706K in Q3 2024. 115 funds tracked by Wall St. Rank hold MLTX as of Q4 2024.

  • AlphaCentric Advisors reported no remaining MoonLake Immunotherapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 14,000 MoonLake Immunotherapeutics shares in Q4 2024, an estimated $706K.
  • AlphaCentric Advisors first reported a position in MoonLake Immunotherapeutics in Q3 2024 and held it in 1 quarter.
  • AlphaCentric Advisors's MoonLake Immunotherapeutics position peaked at $706K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.